Owning Biotech Launch Stocks Is One Strategy To Capture Upside - Goldman Sachs

Goldman Sachs reiterated their view that owning a group of depressed "launch" stocks in the biotech group can capture either an inflection in launch trajectory or a potential acquisition, although the timing is hard to call.

These comments follow yesterday's preannounced sales updates from Dendreon (Nasdaq: DNDN) and InterMune (Nasdaq: INTM), with Dendreon posting a beat and InterMune a slight miss.

Besides Dendreon and InterMune, Human Genome Sciences (Nasdaq: HGSI) is another stock that fits this bill.

Goldman first mentioned this in their December 15 note.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Goldman Sachs Downgrades Shanghai Jahwa United (600315:CH) to Neutral
• Jefferies Starts LunR Royalties Corp (LUNR:CN) at Buy
• UBS Downgrades Alkane Resources (ALK:AU) to Neutral